Adverse Drug Reactions in Corona Virus Disease Patients Admitted to Intensive Care Unit: An Observational Study.

IF 1.1 Q4 PHARMACOLOGY & PHARMACY

Current drug safety Pub Date : 2023-01-01 DOI:10.2174/1574886317666220513095618

Nazia Nazir, Deepti Chopra, Bharti Bhandari, Jaspreet Kaur Sidhu

{"title":"Adverse Drug Reactions in Corona Virus Disease Patients Admitted to Intensive Care Unit: An Observational Study.","authors":"Nazia Nazir, Deepti Chopra, Bharti Bhandari, Jaspreet Kaur Sidhu","doi":"10.2174/1574886317666220513095618","DOIUrl":null,"url":null,"abstract":"Background: Occurrence of adverse drug reactions (ADRs) in COVID-19 patients has not been extensively studied.Aim: The present study was conducted to analyze the pattern of suspected ADRs in the COVID-19 Intensive Care Unit (ICU).Methods: In this cross-sectional study, all the individual case study reports of patients admitted to the COVID ICU (August-October 2020) were analyzed for type of ADRs, system involved, suspected drug, onset time, time to revert and management.Results: Thirty six patients (out of 395 patients admitted) experienced 44 ADRs. Dermatological manifestations were the most frequent ADRs. Remdesivir was the most common drug associated with ADRs. The female gender, polypharmacy (>5 drugs) and presence of comorbidities were the independent risk factors for the occurrence of ADRs.Conclusion: Use of many of these drugs in COVID-19 is experimental and the literature does not guarantee their safety and efficacy. During these times of uncertainty, the results from the present study reinforce the importance of monitoring patients.","PeriodicalId":10777,"journal":{"name":"Current drug safety","volume":null,"pages":null},"PeriodicalIF":1.1000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current drug safety","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/1574886317666220513095618","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 1

Abstract

Background: Occurrence of adverse drug reactions (ADRs) in COVID-19 patients has not been extensively studied.

Aim: The present study was conducted to analyze the pattern of suspected ADRs in the COVID-19 Intensive Care Unit (ICU).

Methods: In this cross-sectional study, all the individual case study reports of patients admitted to the COVID ICU (August-October 2020) were analyzed for type of ADRs, system involved, suspected drug, onset time, time to revert and management.

Results: Thirty six patients (out of 395 patients admitted) experienced 44 ADRs. Dermatological manifestations were the most frequent ADRs. Remdesivir was the most common drug associated with ADRs. The female gender, polypharmacy (>5 drugs) and presence of comorbidities were the independent risk factors for the occurrence of ADRs.

Conclusion: Use of many of these drugs in COVID-19 is experimental and the literature does not guarantee their safety and efficacy. During these times of uncertainty, the results from the present study reinforce the importance of monitoring patients.

查看原文本刊更多论文

重症监护病房收治的冠状病毒病患者的药物不良反应:一项观察性研究

背景:COVID-19患者药物不良反应(adr)的发生尚未得到广泛研究。目的:分析新型冠状病毒肺炎重症监护病房(ICU)疑似不良反应的发生模式。方法:在本横断面研究中，对2020年8月- 10月收治的COVID ICU患者的所有个案研究报告进行分析，包括不良反应类型、涉及的系统、疑似药物、发病时间、恢复时间和管理。结果:395例住院患者中，36例发生44次不良反应。皮肤病是最常见的不良反应。雷姆德西韦是与不良反应相关的最常见药物。女性、多药(>5种药物)、是否存在合并症是adr发生的独立危险因素。结论:在COVID-19中，许多药物的使用是实验性的，文献并不能保证其安全性和有效性。在这些不确定的时期，本研究的结果加强了监测患者的重要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current drug safety PHARMACOLOGY & PHARMACY-

CiteScore

2.10

自引率

0.00%

发文量

112

期刊介绍： Current Drug Safety publishes frontier articles on all the latest advances on drug safety. The journal aims to publish the highest quality research articles, reviews and case reports in the field. Topics covered include: adverse effects of individual drugs and drug classes, management of adverse effects, pharmacovigilance and pharmacoepidemiology of new and existing drugs, post-marketing surveillance. The journal is essential reading for all researchers and clinicians involved in drug safety.